{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:38:47Z","timestamp":1759541927253,"version":"3.38.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This research was funded by Scientific foundation of Zhejiang Medical and Science Project.","award":["2024KY021"],"award-info":[{"award-number":["2024KY021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92590-9","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:22:29Z","timestamp":1741706549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function"],"prefix":"10.1038","volume":"15","author":[{"given":"Qiong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xufan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"8","key":"92590_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.35128","volume":"130","author":"TB Kratzer","year":"2024","unstructured":"Kratzer, T. B. et al. Lung cancer statistics, 2023. Cancer 130(8), 1330\u20131348 (2024).","journal-title":"Cancer"},{"key":"92590_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/resp.13870","volume":"25","author":"SK Vinod","year":"2020","unstructured":"Vinod, S. K. & Hau, E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirology 25, 61\u201371 (2020).","journal-title":"Respirology"},{"issue":"1","key":"92590_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.annonc.2019.10.003","volume":"31","author":"D De Ruysscher","year":"2020","unstructured":"De Ruysscher, D. et al. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Ann. Oncol. 31(1), 41\u201349 (2020).","journal-title":"Ann. Oncol."},{"issue":"4","key":"92590_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11864-019-0624-7","volume":"20","author":"DS Bryan","year":"2019","unstructured":"Bryan, D. S. & Donington, J. S. The role of surgery in management of locally advanced non-small cell lung cancer. Curr. Treat. Options Oncol. 20(4), 27 (2019).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"92590_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong, L. et al. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal. Transduct. Target. Therapy 6(1), 1\u201348 (2021).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"92590_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01121-2","volume":"14","author":"U Majeed","year":"2021","unstructured":"Majeed, U., Manochakian, R., Zhao, Y. & Lou, Y. Targeted therapy in advanced non-small cell lung cancer: Current advances and future trends. J. Hematol. Oncol. 14, 1\u201320 (2021).","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"92590_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/diagnostics10080521","volume":"10","author":"R Bruno","year":"2020","unstructured":"Bruno, R. & Fontanini, G. Next generation sequencing for gene fusion analysis in lung cancer: A literature review. Diagnostics 10(8), 521 (2020).","journal-title":"Diagnostics"},{"issue":"10","key":"92590_CR8","doi-asserted-by":"publisher","first-page":"7816","DOI":"10.3390\/curroncol29100618","volume":"29","author":"Y Xiang","year":"2022","unstructured":"Xiang, Y. et al. Therapeutic advances of rare ALK fusions in non-small cell lung cancer. Curr. Oncol. 29(10), 7816\u20137831 (2022).","journal-title":"Curr. Oncol."},{"issue":"21","key":"92590_CR9","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw, A. T. et al. First-line lorlatinib or Crizotinib in advanced ALK-positive lung cancer. N. Engl. J. Med. 383(21), 2018\u20132029 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"92590_CR10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jtho.2022.08.018","volume":"17","author":"S-H-I Ou","year":"2022","unstructured":"Ou, S-H-I. et al. Efficacy of brigatinib in patients with advanced ALK-positive NSCLC who progressed on alectinib or ceritinib: ALK in lung cancer trial of brigAtinib-2 (ALTA-2). J. Thorac. Oncol. 17(12), 1404\u20131414 (2022).","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"92590_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jtho.2017.11.117","volume":"13","author":"I Letovanec","year":"2018","unstructured":"Letovanec, I. et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: Results from the European thoracic oncology platform lungscape project. J. Thorac. Oncol. 13(3), 413\u2013425 (2018).","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"92590_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/jclinpath-2021-207408","volume":"75","author":"U Batra","year":"2022","unstructured":"Batra, U. et al. IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: All questions answered? J. Clin. Pathol. 75(6), 405\u2013409 (2022).","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"92590_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/1878-0261.13348","volume":"17","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer. Mol. Oncol. 17(5), 765\u2013778 (2023).","journal-title":"Mol. Oncol."},{"issue":"3","key":"92590_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtho.2020.10.156","volume":"16","author":"W Li","year":"2021","unstructured":"Li, W. et al. Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC. J. Thorac. Oncol. 16(3), 404\u2013418 (2021).","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"92590_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12916-022-02362-9","volume":"20","author":"W Li","year":"2022","unstructured":"Li, W. et al. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer. BMC Med. 20(1), 160 (2022).","journal-title":"BMC Med."},{"issue":"2","key":"92590_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/biomedicines12020297","volume":"12","author":"H Parvaresh","year":"2024","unstructured":"Parvaresh, H., Roozitalab, G., Golandam, F., Behzadi, P. & Jabbarzadeh Kaboli, P. Unraveling the potential of ALK-targeted therapies in non-small cell lung cancer: Comprehensive insights and future directions. Biomedicines 12(2), 297 (2024).","journal-title":"Biomedicines"},{"key":"92590_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-016-1061-z","volume":"14","author":"YJ Cha","year":"2016","unstructured":"Cha, Y. J., Kim, H. R. & Shim, H. S. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. J. Transl. Med. 14, 1\u201310 (2016).","journal-title":"J. Translational Med."},{"issue":"23","key":"92590_CR18","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon, B. J. et al. First-line Crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371 (23), 2167\u20132177 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"92590_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","volume":"17","author":"AT Shaw","year":"2016","unstructured":"Shaw, A. T. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol. 17(2), 234\u2013242 (2016).","journal-title":"Lancet Oncol."},{"issue":"10","key":"92590_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","volume":"15","author":"SM Gadgeel","year":"2014","unstructured":"Gadgeel, S. M. et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study. Lancet Oncol. 15(10), 1119\u20131128 (2014).","journal-title":"Lancet Oncol."},{"issue":"5","key":"92590_CR21","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","volume":"18","author":"RC Doebele","year":"2012","unstructured":"Doebele, R. C. et al. Mechanisms of resistance to Crizotinib in patients with ALK gene rearranged non\u2013small cell lung cancer. Clin. Cancer Res. 18(5), 1472\u20131482 (2012).","journal-title":"Clin. Cancer Res."},{"key":"92590_CR22","doi-asserted-by":"crossref","unstructured":"Doebele, R. C. et al. Analysis of resistance mechanisms To ALK kinase inhibitors in ALK\u2009+\u2009NSCLC patients (American Society of Clinical Oncology, 2012).","DOI":"10.1200\/jco.2012.30.15_suppl.7504"},{"issue":"1","key":"92590_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2015.03.028","volume":"362","author":"AG Iyevleva","year":"2015","unstructured":"Iyevleva, A. G. et al. Novel ALK fusion partners in lung cancer. Cancer Lett. 362(1), 116\u2013121 (2015).","journal-title":"Cancer Lett."},{"key":"92590_CR24","doi-asserted-by":"publisher","first-page":"596937","DOI":"10.3389\/fonc.2020.596937","volume":"10","author":"J Kang","year":"2020","unstructured":"Kang, J. et al. Complex ALK fusions are associated with better prognosis in advanced non-small cell lung cancer. Front. Oncol. 10, 596937 (2020).","journal-title":"Front. Oncol."},{"key":"92590_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11523-019-00631-x","volume":"14","author":"Y Su","year":"2019","unstructured":"Su, Y. et al. Distribution of ALK fusion variants and correlation with clinical outcomes in Chinese patients with non-small cell lung cancer treated with Crizotinib. Target. Oncol. 14, 159\u2013168 (2019).","journal-title":"Target. Oncol."},{"issue":"1","key":"92590_CR26","first-page":"100116","volume":"2","author":"VW Zhu","year":"2021","unstructured":"Zhu, V. W. et al. A novel sequentially evolved EML4-ALK variant 3 G1202R\/S1206Y double mutation in cis confers resistance to lorlatinib: A brief report and literature review. JTO Clin. Res. Rep. 2(1), 100116 (2021).","journal-title":"JTO Clin. Res. Rep."},{"issue":"6","key":"92590_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jtho.2020.02.007","volume":"15","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Detection of nonreciprocal\/reciprocal ALK translocation as poor predictive marker in patients with first-line crizotinib-treated ALK-rearranged NSCLC. J. Thorac. Oncol. 15(6), 1027\u20131036 (2020).","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"92590_CR28","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1158\/1541-7786.Mcr-18-0171","volume":"16","author":"MA Childress","year":"2018","unstructured":"Childress, M. A. et al. ALK fusion partners impact response to ALK Inhibition: Differential effects on sensitivity, cellular phenotypes, and biochemical properties. Mol. Cancer Res. 16(11), 1724\u20131736. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-18-0171 (2018). Epub 2018\/07\/14.","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"92590_CR29","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1002\/1878-0261.13509","volume":"17","author":"S Zhou","year":"2023","unstructured":"Zhou, S. et al. Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: A multicenter study. Mol. Oncol. 17(10), 2200\u20132212 (2023).","journal-title":"Mol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92590-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92590-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92590-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:22:36Z","timestamp":1741706556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92590-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92590"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92590-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8437"}}